60 DEGREES PHARMACEUTICALS, INC.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
SXTP$0.52-4.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Condensed Statements of Cash Flows
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)
| For the Three Months Ended March 31, · 2026 · 2025 | ||||
|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||
| Net Loss | $(2,090,155) | $(1,877,301) | ||
| Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities: | ||||
| Depreciation | 16,700 | 6,694 | ||
| Amortization | 9,165 | 10,103 | ||
| Amortization of Capitalized Share-Based Payments | 44,578 | 44,118 | ||
| Share-Based Compensation under Equity Incentive Plan | 79,524 | 142,645 | ||
| Change in Fair Value of Derivative Liabilities | 4,567 | (5,105) | ||
| Change in Inventory Reserve | (251,677) | - | ||
| Changes in Operating Assets and Liabilities: | ||||
| Accounts Receivable | 173,808 | (1,495) | ||
| Prepaid and Other Assets | (742,717) | 131,689 | ||
| Inventory | (2,002) | (330,474) | ||
| Accounts Payable and Accrued Liabilities | 11,735 | 261,905 | ||
| Accrued Interest, net | 4,915 | 19,855 | ||
| Net Cash Used in Operating Activities | (2,741,559) | (1,597,366) | ||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||
| Capitalization of Patents | - | (2,804) | ||
| Purchases of Fixed Assets | (30,000) | (2,678) | ||
| Acquisition of Intangibles | (11,440) | - | ||
| Maturities of Short-Term Investments | 1,235,000 | 1,708,000 | ||
| Net Cash Provided by Investing Activities | 1,193,560 | 1,702,518 | ||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||
| Net Proceeds from ATM Offering | 3,369,752 | - | ||
| Net Proceeds from January 2025 Offering | - | 804,346 | ||
| Net Proceeds from February 2025 Offering | - | 908,627 | ||
| Shares Withheld for Net Share Settlement of Performance Bonuses | - | (18,000) | ||
| Proceeds from Exercise of Pre-Funded Warrants | - | 1,926 | ||
| Net Cash Provided by Financing Activities | 3,369,752 | 1,696,899 | ||
| Effect of Exchange Rate Changes on Cash | 5,942 | (9,904) | ||
| Change in Cash and Cash Equivalents | 1,827,695 | 1,792,147 | ||
| Cash and Cash Equivalents—Beginning of Period | 1,510,065 | 1,659,353 | ||
| Cash and Cash Equivalents—End of Period | $3,337,760 | $3,451,500 | ||
| NONCASH INVESTING/FINANCING ACTIVITIES | ||||
| Purchases of Fixed Assets included in Accounts Payable | $ | - | $10,000 | |
| Capitalized Patent Costs included in Accounts Payable | $16,576 | $ | - | |
| Gross Shares Issued for Annual Performance Bonuses | $ | - | $121,544 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.